{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:56:12Z","timestamp":1777632972421,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["ZY2022009"],"award-info":[{"award-number":["ZY2022009"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","award":["KYYW202311"],"award-info":[{"award-number":["KYYW202311"]}],"id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Yes\u2010associated protein (YAP) is a major downstream nuclear coactivator of the Hippo pathway and is activated during myocardial hypertrophy. Verteporfin, a YAP inhibitor, may serve as a potential treatment for myocardial hypertrophy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    This study was aimed at exploring the role and underlying mechanisms of verteporfin in isoproterenol (ISO)\u2010induced myocardial hypertrophy both in vivo and in vitro.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    GSE18801 directs our focus toward the Hippo pathway role in myocardial hypertrophy. Using an ISO\u2010induced myocardial hypertrophy rat model, YAP expression and localization were observed through Western blot and immunofluorescence. Histopathological analysis was performed to evaluate cardiomyocyte cross\u2010sectional area, and echocardiographic examinations were conducted to assess cardiac function. In vitro, primary neonatal rat cardiomyocytes (NRCMs) were cultured with conditioned medium from cardiac fibroblasts (CF\u2010CM) treated with ISO to observe cell hypertrophy. Mechanistically, GSE203358 dataset analysis, enzyme\u2010linked immunosorbent assay (ELISA), and Western blot were utilized to investigate the effects of ISO and verteporfin on IL\u20106, STAT3, and p\u2010STAT3 levels in CFs. Subsequently, the changes in the IL\u20106\/STAT3 pathway were evaluated in CFs treated with ISO and verteporfin. Additionally, recombinant IL\u20106 and IL\u20106 inhibitor were applied to CMs treated with CF\u2010CM to observe changes in cardiomyocyte size.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Verteporfin improved cardiac performance in rats receiving ISO. In cultured NRCM, both ISO and CF\u2010CM treated with ISO could induce cardiomyocyte hypertrophy. Verteporfin did not attenuate ISO\u2010induced cardiomyocyte hypertrophy. However, it could attenuate hypertrophy induced by the CF\u2010CM treated with ISO. GSE203358 indicated the involvement of the IL\u20106\/STAT3 pathway in the presence of verteporfin in CFs. Additionally, verteporfin reduces IL\u20106 production in cultured CFs subjected to ISO treatment. Notably, the effects of verteporfin on NRCM were reversed by IL\u20106.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Verteporfin protects the heart against ISO\u2010induced myocardial hypertrophy by regulating IL\u20106\/STAT3 in cardiac fibroblasts.\n                  <\/jats:p>","DOI":"10.1155\/cdr\/2852780","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:49:36Z","timestamp":1756385376000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Verteporfin Mitigates Isoproterenol\u2010Induced Myocardial Hypertrophy by Attenuating IL\u20106\/STAT3 in Cardiac Fibroblasts"],"prefix":"10.1155","volume":"2025","author":[{"given":"Sunpeng","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbiao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianshe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-6712","authenticated-orcid":false,"given":"Junming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4933-9406","authenticated-orcid":false,"given":"Peifeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140055"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-015-1477-x"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000043825.01705.1b"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.302317"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147191"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00005.2014"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-013118-111829"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.004251"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-019-1262-z"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313143"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.288"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0007-1"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0063-3"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.314048"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.436311"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306624"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313192110"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14005"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2015.0086"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2005.12.005"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006123"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-014-0435-8"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2932"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.15137"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cdr\/2852780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/cdr\/2852780","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cdr\/2852780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:50:15Z","timestamp":1773769815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/cdr\/2852780"}},"subtitle":[],"editor":[{"given":"Hangang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/cdr\/2852780"],"URL":"https:\/\/doi.org\/10.1155\/cdr\/2852780","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2852780"}}